Overall, Lumacaftor was identified as a potent inhibitor of DUSP18 phosphatase activity, of the DUSP18-USF1-SREBP2 TF cascade and of cholesterol biosynthesis in CRC cells, with little evidence of toxicity. The gene discussed is SREBF2; the disease is colorectal carcinoma.